| Company Name | Exchange | Ticker | Last Price | Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Pulse Seismic Inc | TSX | PSD | 3.19 | 189.9 | Upgrade to hold from sell | Gabriel Leung | Paradigm Capital Inc | 3.00 | -6.0% |
| TAG Oil Ltd | TSX | TAO | 2.72 | 174.2 | Upgrade to neutral from underperform | David Popowich | Macquarie | 3.50 | 28.7% |
| Dollarama Inc | TSX | DOL | 91.28 | 6,113.5 | Upgrade to buy from hold | Keith E Howlett | Desjardins Securities | 99.00 | 8.5% |
| TECSYS Inc | TSX | TCS | 6.40 | 73.9 | Initiate with buy | Nick Agostino | Laurentian Bank Securities | 8.25 | 28.9% |
| Canexus Corp | TSX | CUS | 4.67 | 851.1 | Downgrade to reduce from hold | Damir Gunja | TD Securities | 4.00 | -14.3% |
Paradigm Capital Inc upgraded Pulse Seismic Inc (TSX: PSD), engaged in the acquisition, marketing and licensing of two-dimensional (2D) and three-dimensional (3D) seismic data for the energy sector, to hold from sell increasing its price target to C$3.00 from C$2.75, indicating a downside of 6% from current levels.
TAG Oil Ltd (TSX: TAO), an oil and gas exploration and production company, was upgraded to neutral from underperform at Macquarie with a price target of C$3.50, indicating an upside of 28.7% from current levels.
Desjardins Securities upgraded Dollarama Inc (TSX: DOL), engaged in offering a range of consumer products and general merchandise for everyday use, in addition to seasonal products, to buy from hold with a price target of C$99.00, indicating an upside of 8.5% from current levels.
Laurentian Bank Securities initiated coverage on TECSYS Inc (TSX: TCS), a supply chain management (SCM) provider of powerful warehouse, transportation and distribution management software solutions and industry expert services, with a buy rating assigning a 12-month price target of C$8.25, indicating an upside of 28.9% from current levels.
TD Securities downgraded Canexus Corp (TSX: CUS), engaged in manufacturing a wide range of chemical products, to reduce from hold lowering its price target to C$4.00 from C$5.00, indicating a downside of 14.3% from current levels.
| Company Name | Exchange | Ticker | Last Price |
Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Golar LNG Ltd | NASDAQ | GLNG | 60.42 | 5,635.7 | Upgrade to hold from strong sell | Axel Styrman | Nordea Equity Research | 63.00 | 4.3% |
| Athlon Energy Inc | NYSE | ATHL | 48.03 | 4,664.9 | Upgrade to buy from neutral | Betty Jiang | UBS | 58.00 | 20.8% |
| Alliance Fiber Optic Products Inc | NASDAQ | AFOP | 19.96 | 368.7 | Initiate with buy | Christopher J Longiaru | Sidoti & Company LLC | 28.00 | 40.3% |
| Aerie Pharmaceuticals Inc | NASDAQ | AERI | 25.31 | 593.2 | Initiate with buy | Dr Corey Davis | Canaccord Genuity Corp | 40.00 | 58.0% |
| Regado Biosciences Inc | NASDAQ | RGDO | 2.81 | 94.4 | Downgrade to underperform from outperform | Dr Jim Birchenough | BMO Capital Markets | 1.00 | -64.4% |
Nordea Equity Research upgraded Golar LNG Ltd (NASDAQ: GLNG), owner and operator of liquefied natural gas (LNG) carriers and floating storage regasification units, to hold from strong sell increasing its price target to $63.00 from $31.00, indicating an upside of 4.3% from current levels.
Athlon Energy Inc (NYSE: ATHL), an oil and natural gas exploration and production company, was upgraded to buy from neutral at UBS raising its price target to $58.00 from the earlier target of $45.00, indicating an upside of 20.8% from current levels.
Sidoti & Company LLC initiated coverage on Alliance Fiber Optic Products Inc (NASDAQ: AFOP), a designer, manufacturer, and marketer of a variety of high performance fiber optic components and modular solutions, with a buy rating assigning a 12-month price target of $28.00, indicating an upside of 40.3% from current levels.
Coverage on Aerie Pharmaceuticals Inc (NASDAQ: AERI), a clinical stage pharmaceutical company focused on the discovery, development, and distribution of pharmaceutical products for the treatment of glaucoma and other eye diseases, was initiated with a buy at Canaccord Genuity Corp with a 12-month price target of $40.00, indicating an upside of 58% from current levels.
BMO Capital Markets downgraded Regado Biosciences Inc (NASDAQ: RGDO), a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, to underperform from outperform lowering its price target to $1.00 from $12.00, indicating a downside of 64.4% from current levels.
